Mark Harwood is a highly experienced individual with an outstanding commercial track record in the medical device industry. He was previously President and CEO of ArjoHuntleigh in Roselle, US and subsequent to that Vice President of Baxter International Inc. (Global) based in Chicago, IL, US. He then moved on to become President of RF Technologies (North America & EMEA) based in Brookfield WI, US. He has also gained extensive experience outside of the US, as Managing Director for Arjo Med AB, UK & Ireland.
Mark is a native Oxonian but has strong roots in East Anglia where he now resides. He has wide-ranging experience in medical device technology with an outstanding commercial track record and is a strong team builder. Mark also has extensive regulatory and quality experience, which is very relevant to PneumaCare as they are finalising their FDA 510k approval in the US.
He has extensive regulatory and quality experience, which is very relevant to PneumaCare as they are finalising their FDA 510k approval in the US.
"I am very excited to join PneumaCare", said Mark Harwood, new CEO of the Cambridge-based company. "PneumaCare represents the very best in innovation for medical imaging and I am looking forward to working with the team, increasing revenue and brand awareness in core markets, providing our Customers and stakeholders an attractive return on investment and to build long term business relationships with them".
Dr. Bill Mason, Chairman of PneumaCare, commented, "We are very fortunate to have identified Mark Harwood as the new Chief Executive Officer of PneumaCare. He has an engineering and marketing background. This includes wide experience of both growing small companies in the medical device space, as well as managing large teams of several hundred people involved in commercial, manufacturing and regulatory aspects of the businesses with which he has been involved. His experience includes critical and long-term hospital care as well as special needs patients. He has a strong global track record in Europe and North America. He arrives at PneumaCare at a critical time in its development and our Board believes he will play a pivotal role in taking the Company to the next stage of its commercial and technology development and beyond."
________________________________________________________